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The development of vaccines is one of the most important
public health achievements. However, as the incidence of
vaccine-preventable diseases has decreased, the general
public has become increasingly concerned about vaccine
safety. Vaccine safety is evaluated extensively through
animal safety studies, clinical trials, and post-licensure sur-
veillance. Safety monitoring in post-licensure surveillance
has relied mainly on passive reporting systems such as the
Vaccine Adverse Event Reporting System in the United
States and epidemiological studies.
Vaccine safety profiles cannot necessarily be general-
ized to developing countries, where the incidence, type
and severity of serious adverse events may differ signifi-
cantly because of local environmental and genetic influ-
ences[1]. With the recent introduction of newly
developed vaccines in sub-Saharan Africa (e.g., pneumo-
coccal and rotavirus vaccines), the extensive use of
established vaccines in preventive mass vaccination cam-
paigns (e.g., yellow fever vaccine), and the planned
introduction of vaccines for use primarily in resource-
poor settings (e.g., malaria vaccine), there is an increased
need for effective surveillance of serious adverse events
following immunization (AEFI). Compared to high-
income countries, few low-income economies have func-
tional national pharmacovigilance (PV) systems in place,
due primarily to a lack of resources, infrastructure and
local PV expertise. The importance of functional
national PV systems has recently been underlined with
the implementation of yellow fever (YF) mass campaigns
as part of the Yellow Fever Initiative (YFI).
The recent and novel use of YF vaccine for preventa-
tive mass vaccination campaigns in sub-Saharan Africa
has increased the urgency of establishing functional PV
systems. Between 2006 and 2013, the YFI will distri-
bute vaccines to residents of high-risk areas in 12
West and Central African countries. A condition of
funding from the GAVI Alliance is the implementation
of AEFI surveillance. To address this requirement,
AMP and WHO have provided technical support,
including the development of surveillance tools (e.g.,
operational guide, notification and investigation forms,
standard operating procedures for taking and trans-
porting biological samples), the introduction of active
case finding methods, and the creation and training of
national expert committees to review and classify sus-
pected serious AEFIs. Reference laboratories, including
the Institut Pasteur in Cameroon, and the Robert Koch
Institute in Germany provided diagnostic test results
to facilitate the YF AEFI classification process. Best
practices have been shared between different countries
and African-based consultants have been trained to
become local experts. Their expertise is now being
requested for AEFI surveillance of additional vaccines
such as the serogroup A meningococcal conjugate
vaccine.
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